跳至主要内容
临床试验/EUCTR2013-003320-36-DE
EUCTR2013-003320-36-DE进行中(未招募)1 期

Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study)

Allergan Limited0 个研究点目标入组 310 人开始时间: 2014年6月3日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
310

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Male or female patients 55 years of age or older as assessed at Screening Visit 1
  • The study eye must have:
  • Diagnosis of GA secondary to AMD, as assessed with fundus autofluorescence (FAF) at Screening Visit 1 and confirmed by the central reading center (CRC); these atrophic areas consist of funduscopically visible discrete areas characterized by a marked decrease in fundus autofluorescence intensity and loss of outer-retinal layers with choroidal signal enhancement as assessed with SD-OCT.
  • Areas of atrophy must be multifocal lesions that contain all of the following characteristics:
  • - At least one focal lesion must be equal to or larger than 0.2 mm2
  • - The total lesion area must be greater than 1.25 mm2, but not larger than 18 mm2
  • - The presence of banded or diffuse perilesional hyper-autofluorescence evident on fundus autofluorescence examination.
  • - The distance between the optic disc or peripapillary atrophy and any atrophic lesion must be greater than 300 µm
  • Presence of drusen, yellow or white accumulations of extracellular material formed between Bruch's membrane and the retina pigmented epithelial cell layer, assessed with fundus photography and/or SD-OCT at Screening Visit 1 and confirmed by the CRC
  • - BCVA better than or equal to 45 letters (20/125 Snellen equivalent) at Screening Visit 1 and the Baseline visit as assessed using the standard ETDRS (Early Treatment of Diabetic Retinopathy Study) visual acuity protocol
  • - Clear ocular media and adequate pupil dilation to permit good quality retinal imaging as assessed at Screening Visit 1 and confirmed by the CRC
  • - For patients participating in microperimetry assessments: abitity to complete repeat assessments of scotopic/mesopic microperimetry with an intra-visit, mean, retinal sensitivity reproducibility of 6 dB or less, as assessed at Screening Visit 2 and confirmed by the CRC
  • The Fellow Eye must have Standard BCVA of 34 letters (Snellen equivalent 20/200) or better at Screening Visit 1
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 160
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 160

排除标准

  • History or evidence of choroidal neovascularization in either eye at Screening Visit 1, as confirmed by the CRC
  • Diagnosis of GA secondary to AMD that presents as unifocal atrophic lesions, lesions with no perilesional hyper-autofluorescence, lesions with only focal areas of perilesional hyper-autofluorescence on FAF examination of the study eye at Screening Visit 1 and confirmed by the CRC
  • Spherical equivalent of the refractive error of -6 diopters of myopia or worse (prior to cataract or refractive surgery) in the study eye at Screening Visit 1

研究者

相似试验